The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Corvert     N-[4-[4-(ethyl-heptyl-amino)- 1-hydroxy...

Synonyms: Ibutilida, Ibutilide, Ibutilidum, CHEMBL533, Corvert (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07753


Psychiatry related information on C07753

  • OBJECTIVE: The primary objective of this piggyback cost-effectiveness analysis of the TIME study was to compare the cost per successful conversion of atrial fibrillation (AF) for ibutilide in the presence and absence of magnesium prophylaxis [5].
  • METHODS: Using a standardized physical activity protocol, the QT interval was assessed over a broad range of heart rates before and after an infusion of ibutilide (4.75 microg/kg) that produced a stable 15- to 20-ms QT prolongation in consenting normal subjects (9 men and 9 women) [6].

High impact information on C07753


Chemical compound and disease context of C07753


Biological context of C07753


Anatomical context of C07753


Associations of C07753 with other chemical compounds

  • Incremental pacing was performed to measure the conduction velocity along the isthmus and lateral wall, and extrastimulation was performed to evaluate atrial refractory period in the baseline state and after intravenous infusion of ibutilide, propafenone, and amiodarone [9].
  • METHODS AND RESULTS: Right atrial monophasic action potentials were recorded during 148 episodes of AFL (n=89) or AF (n=59) in 136 patients treated with intravenous ibutilide (n=73) or placebo (n=22) as participants in randomized, double-blinded comparative studies or intravenous procainamide (n=53) in a concurrent open-label study [13].
  • METHODS: Seventy-one patients with AF (n = 48) or AFL (n = 23), receiving propafenone 300 to 900 mg/day (n = 46) or flecainide 100 to 300 mg/day (n = 25), presented for ibutilide (2.0 mg) cardioversion [22].
  • Structural determinants of HERG channel block by clofilium and ibutilide [23].
  • Ten minutes after perfusion in the presence of vehicle or ibutilide, hearts were perfused with the ATP-dependent potassium channel opener, pinacidil (1.25 microM) and subjected to a 12-min hypoxic period followed by 40 min of reoxygenation, or until the onset of VF [24].

Gene context of C07753

  • Drugs that inhibit CYP3A4 (such as erythromycin) and/or the renal transport system (such as triamterene) may interact with dofetilide.It appears that the potential for pharmacokinetic interactions between ibutilide and other drugs is low [25].
  • This is because ibutilide is not metabolised by CYP3A4 or CYP2D6 [25].
  • Ibutilide prolongs MAPD and ERP of human atrium and ventricle without reverse use-dependency [26].
  • CAVB biopsies had significantly longer APDs, a larger dispersion of repolarization and showed more EADs in the presence of ibutilide than SR biopsies [27].
  • Ibutilide induced slowing of AF was more intense and more rapid in patients who converted to sinus rhythm than in those who did not (25 +/- 5% vs 18 +/- 14% drop in rate, t1/2 3.4 minutes vs 6.3 minutes, P = 0.002) [28].

Analytical, diagnostic and therapeutic context of C07753

  • BACKGROUND: Ibutilide is an action potential-prolonging antiarrhythmic currently in clinical trials [17].
  • The purpose of this multicenter study was to determine the efficacy and safety of repeated doses of intravenous ibutilide, a class III antiarrhythmic drug, in terminating atrial fibrillation or flutter [3].
  • This study reliably discerned 5- to 10-ms changes in corrected QT in the ibutilide active control group [29].
  • However, antiarrhythmic doses of MK499 and ibutilide also consistently and significantly increased ventricular relative (+9.9 and +7.6%, respectively) and effective (+10.4 and +9.9%, respectively) refractory periods, rate-corrected ECG QTc (+6.7 and +7.8%, respectively), and paced QT (+7.3 and +8.5%, respectively) intervals [30].
  • Safety data were reviewed from several controlled clinical trials of ibutilide, a new class III antiarrhythmic drug recently approved for the acute interruption of atrial fibrillation and flutter [31].


  1. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. Oral, H., Souza, J.J., Michaud, G.F., Knight, B.P., Goyal, R., Strickberger, S.A., Morady, F. N. Engl. J. Med. (1999) [Pubmed]
  2. Acute renal failure after ibutilide. Franz, M., Geppert, A., Kain, R., Hörl, W.H., Pohanka, E. Lancet (1999) [Pubmed]
  3. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Stambler, B.S., Wood, M.A., Ellenbogen, K.A., Perry, K.T., Wakefield, L.K., VanderLugt, J.T. Circulation (1996) [Pubmed]
  4. Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. Roden, D.M. Circulation (1996) [Pubmed]
  5. Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation. Coleman, C.I., Kalus, J.S., White, C.M., Spencer, A.P., Tsikouris, J.P., Chung, J.O., Kenyon, K.W., Ziska, M., Kluger, J., Reddy, P. PharmacoEconomics. (2004) [Pubmed]
  6. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Indik, J.H., Pearson, E.C., Fried, K., Woosley, R.L. Heart rhythm : the official journal of the Heart Rhythm Society. (2006) [Pubmed]
  7. Drug-induced QT prolongation in women during the menstrual cycle. Rodriguez, I., Kilborn, M.J., Liu, X.K., Pezzullo, J.C., Woosley, R.L. JAMA (2001) [Pubmed]
  8. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Glatter, K., Yang, Y., Chatterjee, K., Modin, G., Cheng, J., Kayser, S., Scheinman, M.M. Circulation (2001) [Pubmed]
  9. Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. Tai, C.T., Chen, S.A., Feng, A.N., Yu, W.C., Chen, Y.J., Chang, M.S. Circulation (1998) [Pubmed]
  10. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. Volgman, A.S., Carberry, P.A., Stambler, B., Lewis, W.R., Dunn, G.H., Perry, K.T., Vanderlugt, J.T., Kowey, P.R. J. Am. Coll. Cardiol. (1998) [Pubmed]
  11. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Reisinger, J., Gatterer, E., Lang, W., Vanicek, T., Eisserer, G., Bachleitner, T., Niemeth, C., Aicher, F., Grander, W., Heinze, G., Kühn, P., Siostrzonek, P. Eur. Heart J. (2004) [Pubmed]
  12. Current treatment recommendations in antiarrhythmic therapy. Van Gelder, I.C., Brügemann, J., Crijns, H.J. Drugs (1998) [Pubmed]
  13. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Stambler, B.S., Wood, M.A., Ellenbogen, K.A. Circulation (1997) [Pubmed]
  14. Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Foster, R.H., Wilde, M.I., Markham, A. Drugs (1997) [Pubmed]
  15. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Danielsson, B.R., Skold, A.C., Azarbayjani, F. Curr. Pharm. Des. (2001) [Pubmed]
  16. Electrophysiology and pharmacology of ibutilide. Naccarelli, G.V., Lee, K.S., Gibson, J.K., VanderLugt, J. Am. J. Cardiol. (1996) [Pubmed]
  17. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Yang, T., Snyders, D.J., Roden, D.M. Circulation (1995) [Pubmed]
  18. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. Guo, G.B., Ellenbogen, K.A., Wood, M.A., Stambler, B.S. J. Am. Coll. Cardiol. (1996) [Pubmed]
  19. Altered response to ibutilide in a heart failure model. Chugh, S.S., Johnson, S.B., Packer, D.L. Cardiovasc. Res. (2001) [Pubmed]
  20. High-density mapping of pulmonary veins and left atrium during ibutilide administration in a canine model of sustained atrial fibrillation. Chou, C.C., Zhou, S., Tan, A.Y., Hayashi, H., Nihei, M., Chen, P.S. Am. J. Physiol. Heart Circ. Physiol. (2005) [Pubmed]
  21. Electrophysiological effects of ibutilide on the delayed rectifier K(+) current in rabbit sinoatrial and atrioventricular node cells. Sato, N., Tanaka, H., Habuchi, Y., Giles, W.R. Eur. J. Pharmacol. (2000) [Pubmed]
  22. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. Hongo, R.H., Themistoclakis, S., Raviele, A., Bonso, A., Rossillo, A., Glatter, K.A., Yang, Y., Scheinman, M.M. J. Am. Coll. Cardiol. (2004) [Pubmed]
  23. Structural determinants of HERG channel block by clofilium and ibutilide. Perry, M., de Groot, M.J., Helliwell, R., Leishman, D., Tristani-Firouzi, M., Sanguinetti, M.C., Mitcheson, J. Mol. Pharmacol. (2004) [Pubmed]
  24. Antifibrillatory effects of ibutilide in the rabbit isolated heart: mediation via ATP-dependent potassium channels. Friedrichs, G.S., Chi, L., Black, S.C., Manley, P.J., Oh, J.Y., Lucchesi, B.R. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  25. Potentially significant drug interactions of class III antiarrhythmic drugs. Yamreudeewong, W., DeBisschop, M., Martin, L.G., Lower, D.L. Drug safety : an international journal of medical toxicology and drug experience. (2003) [Pubmed]
  26. Frequency-dependent electrophysiological effect of ibutilide on human atrium and ventricle. Oshikawa, N., Watanabe, I., Masaki, R., Shindo, A., Kojima, T., Saito, S., Ozawa, Y., Kanmatsuse, K. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. (2001) [Pubmed]
  27. Electrophysiological and proarrhythmic parameters in transmural canine left-ventricular needle biopsies. Verduyn, S.C., Jungschleger, J.G., Stengl, M., Spätjens, R.L., Beekman, J.D., Vos, M.A. Pflugers Arch. (2004) [Pubmed]
  28. Atrial electrophysiological effects of ibutilide infusion in humans. Schwartz, R.A., Langberg, J.J. Pacing and clinical electrophysiology : PACE. (2000) [Pubmed]
  29. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. Beasley, C.M., Mitchell, M.I., Dmitrienko, A.A., Emmick, J.T., Shen, W., Costigan, T.M., Bedding, A.W., Turik, M.A., Bakhtyari, A., Warner, M.R., Ruskin, J.N., Cantilena, L.R., Kloner, R.A. J. Am. Coll. Cardiol. (2005) [Pubmed]
  30. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. Stump, G.L., Wallace, A.A., Regan, C.P., Lynch, J.J. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  31. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Kowey, P.R., VanderLugt, J.T., Luderer, J.R. Am. J. Cardiol. (1996) [Pubmed]
WikiGenes - Universities